Busting the Breast Cancer with AstraZeneca's Gefitinib.

Autor: Chemmalar S; Department of Veterinary Anatomy, Veterinary College and Research Institute, Tamil Nadu Veterinary and Animal Sciences University (TANUVAS), Theni 625534, Tamil Nadu, India.; Natural Medicines and Products Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia., Intan Shameha AR; Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, UPM, Serdang 43400, Selangor, Malaysia., Che Abdullah CA; Biophysics Laboratory, Department of Physics, Faculty of Science, Laboratory of Cancer Research (MAKNA), Institute of Bioscience and Material Synthesis & Characterization Laboratory, Institute of Advanced Technology, UPM, Serdang 43400, Selangor, Malaysia., Ab Razak NA; Natural Medicines and Products Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia., Yusof LM; Department of Companion Animal Medicine and Surgery, Faculty of Veterinary Medicine, UPM, Serdang 43400, Selangor, Malaysia., Ajat M; Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine and Natural Medicines and Product Research Laboratory, Institute of Bioscience, UPM, Serdang 43400, Selangor, Malaysia., Chan KW; Natural Medicines and Products Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia., Abu Bakar Zakaria MZ; Natural Medicines and Products Research Laboratory, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia.; Department of Veterinary Preclinical Sciences, Faculty of Veterinary Medicine, UPM, Serdang 43400, Selangor, Malaysia.
Jazyk: angličtina
Zdroj: Advances in pharmacological and pharmaceutical sciences [Adv Pharmacol Pharm Sci] 2023 Dec 04; Vol. 2023, pp. 8127695. Date of Electronic Publication: 2023 Dec 04 (Print Publication: 2023).
DOI: 10.1155/2023/8127695
Abstrakt: Breast cancer is the most common cancer diagnosed in women, and in 2020, there were 684, 996 deaths due to this disease. Epidermal growth factor receptors (EGFRs) and their respective ligands have been blamed for the pathogenesis and resistance to treatment in specific breast cancer cases. With EGFR having four homologues: EGFR1, EGFR2, EGFR3, and EGFR4, in-depth understanding of EGFR biology led to the discovery of small-molecule inhibitors and antibodies against this receptor. Gefitinib (GEF), a tyrosine kinase inhibitor of EGFR1, possesses a vast potential for treatment against breast cancer and is supported by a multiplicity of experiments. Unfortunately, in clinical trials, GEF did not show the outcomes expected with complete response and disease progress. This is due to incomplete understanding of the molecular mechanisms involved in EGFR signaling and endocrine sensitivity. Hence, additional in-depth experiments are needed regarding various molecular pathways and crosstalk pathways to comprehend GEF's action mechanism thoroughly in breast cancer patients. In this review, the role of EGFR in the development and pathogenesis of breast cancer and the pharmacokinetics and pharmacotherapy of GEF for the treatment of breast cancer have been elaborated. Nanomedicines synthesized with GEF have shown positive experimental response, paving a promising path for GEF against breast cancer.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2023 S. Chemmalar et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje